Close Menu

NEW YORK (GenomeWeb) – Minneapolis-based Bio-Techne, a provider of tools and bioactive reagents for research and clinical diagnostics, said today that it has closed on a strategic equity investment valued at $43 million in Astute Medical, which is marketing a biomarker-based diagnostic test for acute kidney injury.

Bio-Techne said that the deal has been structured to allow it to build a strategic foundation in diagnostics, and includes an option for it to further expand the relationship.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.